Role of permanent cardiac pacing for vasovagal syncope  by Sumiyoshi, Masataka
Review
Role of permanent cardiac pacing for vasovagal syncope
Masataka Sumiyoshi, MDn
Department of Cardiology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-ku, Tokyo 177-8521, Japan
a r t i c l e i n f o
Article history:
Received 13 January 2014
Accepted 3 April 2014
Available online 19 June 2014
Keywords:
Vasovagal syncope
Permanent cardiac pacemaker
Rate-drop response
Closed-loop stimulation
a b s t r a c t
The role of pacemaker therapy for vasovagal syncope (VVS) is still controversial. The ISSUE 3 study led to
reappraisal of pacing therapy (using DDD pacing with the rate-drop response algorithm) for reducing
syncope recurrence in a highly selected patient group (age, Z40 years) with asystolic VVS clinically
documented by implantable loop recorder. However, the role of pacemaker treatment for young (age,
o40 years) VVS patients remains to be established. Psychological sequelae and the burden of the long-
term implanted device should be considered. DDD pacing with closed-loop stimulation seems to be a
promising algorithm; however, we need more data to determine the best pacing algorithm. Multicenter,
prospective mega trials with a randomized and controlled design are needed to resolve these issues.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Vasovagal syncope (VVS) is the most common cause of syn-
cope. VVS is designated as one of the types of reﬂex syncope
(neurally-mediated syncope) in both the Japanese and European
guidelines regarding syncope [1,2]. The phenomenon of VVS
consists of hypotension and bradycardia or asystole. Therefore,
implantation of a permanent pacemaker is thought to be a
reasonable treatment. In carotid sinus syncope, pacing therapy is
regarded as one of the ﬁrst-line treatments in patients with
recurrent syncope and cardioinhibitory response during carotid
sinus massage [1,2]. Although a dominant cardioinhibitory
component has been observed in most patients with carotid sinus
syncope [3], the vasodepressor factor seems to be the main cause
of fainting in most VVS patients. The efﬁcacy of pacing therapy for
VVS has been controversial so far. The purpose of this review is to
assess the historical background and the efﬁcacy of cardiac pacing
in patients with VVS.
2. Clinical experience with pacemaker treatment for vasovagal
syncope before the randomized clinical trial (RCT) era
The data in the 1990s concerning the outcomes of permanent
cardiac pacemaker use in patients with VVS were conﬂicting. The
usual pacemaker therapy, even DDD pacing, could not prevent VVS
during head-up tilt (HUT) testing owing to insufﬁcient efﬁcacy of
the vasodepressor factor [4,5]. Sra et al. [4] found that cardiac
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/joa
Journal of Arrhythmia
http://dx.doi.org/10.1016/j.joa.2014.04.009
1880-4276/& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
n Tel.: þ81 3 5923 3111; fax: þ81 3 5923 3217.
E-mail address: sumi@juntendo.ac.jp
Journal of Arrhythmia 30 (2014) 417–420
pacing for VVS was less effective than drug therapy. Conventional
pacing treatment (i.e., DDD pacing for patients with sinus rhythm
or VVI pacing for patients with atrial ﬁbrillation) did not prevent
hypotension and syncope or presyncope during HUT testing in
VVS patients with asystole or bradycardia [4]. The lack of efﬁcacy
of pacing in these patients suggested that even in patients with a
cardioinhibitory response, hypotension is predominantly due to
vasodepression, whereas vagally mediated bradycardia may play
only a secondary part in the pathogenesis of VVS [4,6]. However, it
was argued that permanent pacemaker therapy may be useful in
preventing syncope in patients with so-called “malignant vasova-
gal cardioinhibitory response,” in which the onset of syncope is
thought to be abrupt [6]. In addition, Sra et al. [4] showed that a
potential beneﬁt of pacing therapy was that cardiac pacing could
diminish the magnitude of hypotension in some VVS patients. This
suggested the idea that early intervention with cardiac pacing
might prevent or at least alleviate hypotension and syncope.
Petersen et al. [7] reported a possible role for permanent pacing in
selected patients with cardioinhibitory malignant VVS in a retro-
spective, uncontrolled 1994 study. Cardiac pacemakers were
implanted in 37 patients. Most of these were programmed to DDI
mode with rate hysteresis. During the follow-up period of 50.2723.9
months, symptomatic improvement occurred in 89% of the patients,
with 62% remaining free of syncope and 27% being completely
symptom free. In 1997, Benditt et al. [8] reported the results of
pacemaker treatment with the rate-drop response (RDR) algorithm
in 28 patients with tilt-positive VVS and induced bradycardia. During
an average follow-up of 6 months, 78% of patients did not faint at all
and an overall 67% reduction in syncope frequency was observed. In
1998, Sheldon et al. [9] also reported efﬁcacy of pacemaker therapy.
They implanted a dual-chamber pacemaker with automatic rate
smoothing in 12 patients with frequent syncope (median: 3 episodes
per month). After implantation, the frequency of syncope decreased
by 93% and quality of life improved markedly.
Although these studies demonstrated the efﬁcacy of pacemaker
treatment for preventing or reducing VVS, all 3 trials were retro-
spective and uncontrolled [10]. Therefore, RCTs of cardiac pacing in
VVS were proposed in the late 1990s.
3. The era of RCTs: is pacemaker efﬁcacy due to a placebo
effect?
Since 1999, several RCTs of pacing therapy for refractory VVS
have been conducted (Table 1).
Flammang et al. [11] reported the efﬁcacy of pacemaker treat-
ment for VVS with a severe cardioinhibitory response identiﬁed by
the adenosine triphosphate test. Twenty patients were randomized
to 2 groups: DDD pacemaker implantation (10 patients) and usual
medical care (10 patients). During a mean follow-up of 52 months,
syncope recurred in 60% of the usual-care patients but in none of
the paced patients (Po0.02). In the North American Vasovagal
Pacemaker Study (VPS) [12], 54 patients were randomly divided
into 2 groups: DDD pacemaker with RDR or no pacemaker. The
results of VPS showed a marked reduction in the risk of syncope
recurrence with pacemaker implantation (relative risk reduction,
85.4%). In the Vasovagal Syncope International Study (VASIS) [13],
42 patients were randomized to receive a DDI pacemaker with rate
hysteresis or no pacemaker. Inclusion criteria were Z3 syncope
episodes over the preceding 2 years and a positive cardioinhibitory
response to HUT testing. During the follow-up period of 3.772.2
years, there was signiﬁcantly less recurrence of syncope in the
pacemaker arm than in the non-pacemaker arm (5% vs. 61%,
P¼0.0006). In the Syncope Diagnosis and Treatment (SYDIT) Study
[14], 93 patients were randomized to receive either a DDD pace-
maker with RDR function or the beta-blocker atenolol. Inclusion
criteria were age 435 years, Z3 syncope episodes in the preceding
2 years, and positive response to HUT testing with relative brady-
cardia. During the mean follow-up of 17.3 months, the recurrence of
syncope was signiﬁcantly lower in the pacemaker group than in the
pharmaceutical treatment group (4.3% vs. 25.5%, P¼0.004). On the
basis of the results of these 3 RCTs, pacing therapy appears to be
effective for the prevention of recurrent syncope in patients with
VVS. However, double-blind randomized trials showed different
outcomes. In the Second Vasovagal Pacemaker Study (VPS II) [15],
100 patients were assigned to receive DDD pacing with RDR or to
have only sensing without pacing (ODO). Inclusion criteria were
history of typical VVS with Z6 overall episodes of syncope or Z3
episodes of syncope in the preceding 2 years and a positive HUT
test. The cumulative risk of syncope at 6 months was not different
between the DDD and ODO groups (31% vs. 40%). In the vasovagal
SYNcope and PACing (SYNPACE) [16] trial, 29 patients with severe
recurrent tilt-induced VVS underwent DDD-RDR pacemaker
implantation and were randomized to pacemaker ON or pacemaker
OFF. During the follow-up of 23.8 months, the recurrence of
syncope showed no signiﬁcant difference (50% in pacemaker ON
and 38% in pacemaker OFF). The median time to ﬁrst syncope
recurrence was also not signiﬁcantly different.
After these 2 double-blind RCTs failed to prove the superiority of
cardiac pacing over placebo in patients affected by VVS, the widely
accepted opinion was that cardiac pacing therapy is not very
effective and that a strong placebo effect exists [17]. The results of
VPS II and SYNPACE were disappointing. However, these 2 trials
included patients with VVS of not only the cardioinhibitory type but
also the vasodepressor and mixed types. Therefore, the question
arises whether pacing therapy could be effective for the cardioinhi-
bitory type of VVS, speciﬁcally that with a prolonged asystole [18].
4. Reappraisal of pacing therapy for vasovagal
syncope: ISSUE 3
The implantable loop recorder (ILR) has advanced the diagnosis
of syncope of uncertain etiology. ILR can record a real-time ECG at
Table 1
Randomized controlled clinical trials of pacemaker treatments for vasovagal syncope.
Trial Reference Year Study design PM system N FU (months) PM effect Recurrent syncope P value
Flammang 11 1999 PM vs. usual care DDD 20 52 Yes 0% vs. 60% o0.02
VPS 12 1999 PM vs. usual care DDD-RDR 54 16 Yesa 22% vs. 70%
VASIS 13 2000 PM vs. no DDI-RH 42 44 Yes 5% vs. 61% 0.0006
SYDIT 14 2001 PM vs. atenolol DDD-RDR 93 17.3 Yes 4.3% vs. 25.5% 0.004
VASIS 2 15 2002 PM-on vs. PM-off DDD-RDR 100 6 No 31% vs. 40% –
SYNPACE 16 2004 PM-on vs. PM-off DDD-RDR 29 23.8 No 50% vs. 38% –
ISSUE 3 22 2012 PM-on vs. PM-off DDD-RDR 77 24 Yes 25% vs. 57% 0.039
PM¼pacemaker; FU¼follow-up duration; RDR¼rate-drop response; and RH¼rate hysteresis.
a Signiﬁcant reduction in the post-randomization risk of syncope in pacemaker patients.
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the time of syncopal episodes. Classically, the results of HUT
testing were used to select patients for pacing in clinical trials
[12–16]. ILR revealed that patients with a tilt-induced asystole did
not always have bradycardia or asystole during the recurrent
episodes of syncope [19,20]. Because the hemodynamic response
during HUT testing does not predict the hemodynamic status
during spontaneous syncope, it follows that the results of HUT
testing cannot predict the efﬁcacy of cardiac pacing [21]. The
Second International Study on Syncope of Uncertain Etiology
(ISSUE 2) [22] revealed the mechanism of spontaneous neurally
mediated syncope documented by ILR: approximately one-half of
syncope events showed a prolonged asystole. It is reasonable that
pacing therapy may be effective when asystole is documented at
the time of syncope. In ISSUE 2 [22], patients with asystolic
syncope treated with pacemakers showed more than 80% relative
risk reduction of syncope recurrence in comparison with
untreated groups. However, ISSUE 2 was not a formal controlled
double-blind trial. Therefore, ISSUE 3, another randomized con-
trolled clinical trial that was designed to assess the apparent
pacing beneﬁt, was conducted [18]. The ISSUE 3 [18] trial was a
double-blind, randomized placebo-controlled study conducted in
29 centers in Europe and Canada. Subjects were limited to those
aged Z40 years and with a history of syncope suggestive of a
vasovagal cause. Subjects were required to have reported 43
episodes in the preceding 2 years and at least 1 in the 6 months
immediately prior to enrollment. The results of ISSUE 3 were
reported in 2012 [23]. Initially, 511 patients received an ILR; 89 of
these had documentation of either syncope with an asystole of
43 s or an asystole 46 s without syncope within 12710 months
and met criteria for pacemaker implantation. Of these, 12 patients
refused randomization. Ultimately, 77 of the 89 patients were
randomly assigned to DDD pacing with RDR (pacemaker ON) or to
sensing only (pacemaker OFF). The data were analyzed on the
intention-to-treat principle. There was syncope recurrence during
the follow-up in 27 patients, 19 of whom had been assigned to
pacemaker OFF and 8 to pacemaker ON. The 2-year estimated
syncope recurrence rate was signiﬁcantly higher in patients with
pacemaker OFF than in those with pacemaker ON (57% vs. 25%,
P¼0.039). The risk of syncope recurrence was reduced by 57%
(95% CI, 4–81%). The ISSUE 3 study demonstrated that pacemaker
therapy is effective in preventing the recurrence of syncope for
selected VVS patients who had cardioinhibitory response docu-
mented by ILR. Prevention could not be ascribed to a placebo
effect. Although ISSUE 3 has led to reappraisal of pacing treatment
for VVS, the role of pacemaker treatment for young (age, o40
years) VVS patients remains to be established. Sra and Akhtar [6]
pointed out that most patients with VVS are relatively young and
have a benign prognosis. Therefore, apart from the efﬁcacy and the
cost of such an intervention, the implications of serious psycho-
logical sequelae and the burden of the long-term implanted device
need to be justiﬁed.
5. What is the best pacing algorithm for vasovagal syncope?
Generally, patients with VVS do not need continuous cardiac
pacing, but require physiological pacing only at the moment of the
vasovagal response. Petersen et al. [7] reported the efﬁcacy of
permanent DDI pacing with rate hysteresis in selected patients
who presented with cardioinhibitory VVS. Previous studies [8,24]
have shown that DDD with the RDR algorithm reduced syncopal
episodes in patients with severe forms of the cardioinhibitory type
of VVS. In the RDR algorithm, the pacemaker senses small
decreases in heart rate of around 10–20 beats per minute (bpm),
then paces at a high rate of 110–120 bpm for 1–2 min. Ammirati
et al. [25] showed that DDD-RDR pacing was preferable to DDD
pacing with rate hysteresis. The ideal device for VVS should sense
the initial heart rate drop and pace early in the episode at a
relatively high rate [25]. The closed-loop stimulation (CLS) pace-
maker algorithm is a system that permanently monitors the
contractile state of the myocardium and converts the intrinsic
information into rate regulation [26]. The concept of the CLS
algorithm for preventing VVS is as follows: the CLS system detects
a change in the contraction dynamics in the early generation phase
of syncope, and counteracts the drop in blood pressure with an
acceleration of the heart rate, preventing the syncope [26]. In
1998, Deharo et al. [27] reported the efﬁcacy of a rate-responsive
pacemaker driven by heart contractility for preventing the vaso-
depressive response. Deharo et al. [28] reported a multicenter,
randomized study using a crossover design for comparison
between DDDR pacing (a basic rate of 60 bpm) driven by contrac-
tility and DDI pacing (a basic rate of 70 bpm) with a rate hysteresis
of 20 bpm. Inclusion criteria were (1) 46 cumulative syncopal
episodes or Z1 syncope within 6 months of a positive HUT test,
and (2) a positive HUT test with bradycardia. After implantation,
the pacemakers were randomly programmed for 2 successive
periods of 6 months to DDDR or DDI mode. Although the
quality-of-life scores were not different, the numbers of episodes
of syncope and presyncope were signiﬁcantly less frequent during
pacing in the DDDR mode (0.0970.29 episodes per person) than
in the DDI mode (0.4870.73 episodes per person) (Po0.05). The
efﬁcacy of the CLS algorithm has been evaluated in several clinical
studies [29–32]. The INotropy controlled pacing in VAsovagal
SYncope (INVASY) study [29] demonstrated that CLS pacing was
more effective than DDI pacing at preventing VVS recurrence in
patients with a cardioinhibitory response to HUT. However, this
study had several limitations: the low number of controls (n¼9),
relatively short-term follow-up (mean, 19 months), and use of DDI
mode programmed at 40 ppm. Kanjwal et al. [30] showed the role
of DDD-CLS pacing in the reduction of the syncope burden for 32
highly symptomatic patients with asystole (410 s) or severe
bradycardia (o30 bpm) documented by IRL or during HUT in
their short-term follow-up study (973 months). Bortnik et al. [31]
reported the long-term (mean, 5.172.9 years) efﬁcacy of DDDR-
CLS pacing in prevention of recurrent VVS. Palmisano et al. [32]
showed the superiority in prevention of the recurrence of syncope
of CLS pacing compared with the RDR algorithm during the long-
term follow-up (mean, 4.473.0 years) in a retrospective analysis.
In 2013, Russo et al. [26] reported the effect of DDD-CLS pacing on
syncope recurrence in VVS patients with a tilt-induced cardioin-
hibitory response in a prospective, randomized, single-blind,
crossover study. The study consisted of 50 patients (mean age,
5375 years) with indication for permanent DDD pacing for tilt-
induced cardioinhibitory VVS. The patients were randomized after
a 1-month period of stabilization to have CLS algorithm features
programmed OFF or ON for 18 months each, using a crossover
design. The numbers of syncopal and presyncopal episodes during
active treatment were lower compared to those registered during
no treatment (syncope: 2 vs. 15; P¼0.007 and presyncope: 5 vs.
30; P¼0.004). The pacing intervention in the early phase of VVS
using the DDD-CLS algorithm seems to have a potential for
preventing not only asystole or bradycardia, but also hypotension.
However, we were unable to draw conclusions as to the best
pacing algorithm for VVS due to the lack of a direct comparison
study between the DDD-CLS algorithm and DDD-RDR pacing in
the prevention of syncope recurrence in VVS.
6. Conclusions
The role of pacemaker therapy for VVS is still controversial.
The ISSUE 3 study caused reappraisal of pacing therapy (using
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DDD-RDR pacing) for reducing syncope recurrence in a limited
group of patients (age, Z40 years) with asystolic VVS clinically
documented by ILR. However, the role of pacemaker treatment for
young (age, o40 years) VVS patients remains to be established.
Psychological sequelae and the burden of the long-term implanted
device should be considered. DDD pacing with CLS seems to be a
promising algorithm; however, we need more data to decide upon
the best pacing algorithm. Multicenter, prospective mega trials
with a randomized and controlled design are needed to resolve
these issues.
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